Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05661708
Other study ID # MUGLA-9
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date December 15, 2022
Est. completion date May 17, 2024

Study information

Verified date May 2024
Source Erzincan Military Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Early treatment of cervical intraepithelial neoplasia (CIN) II-III gives rise to a decrease in the incidence of invasive cervical cancer. Though there is no obvious consensus from randomized studies as to the optimal management of CIN II-III, loop electrosurgical excision procedure (LEEP) is the most extensively used method because of its technical ease, inexpensive, steep learning curve, and low rate of complications. In spite of these benefits, current literature suggests that some patients experience some complications such as postoperative vaginal bleeding, abnormal vaginal discharge, abdominal pain, and infection. These adversely affect the recovery period, increase patient anxiety, readmission to the hospital for further treatment and encumber patients' daily life. Postoperative vaginal bleeding (PVB) is one of the most common and unpleasant of these complications. Its incidence has been reported to vary between 2% to 78%. Many different types of treatments have been applied to avert or diminish PVC such as the use of vasopressin, tranexamic acid, Monsel's solution, and local hemostats (e.g., TachoSil or Tisseel), but these attempts have failed to show precise benefits over routine clinical approaches. Chitosan is a biodegradable, natural polyaminosaccharide with a nontoxic, non-allergenic, positively-charged polysaccharide derived from the deacetylation of chitin. Due to its molecular characteristics, chitosan has been used for improved hemostasis. Furthermore, chitosan has an antimicrobial and wound-healing effect. The current literature concerning the influence of using chitosan after the LEEP is limited to only one trial. The authors of that study reported that using chitosan after the LEEP can reduce vaginal bleeding and enhancing wound healing. However, that study has some limitations. Therefore, investigators designed this randomized trial to assess the effect of local chitosan implementation on postoperative vaginal bleeding and wound healing in LEEP


Recruitment information / eligibility

Status Completed
Enrollment 130
Est. completion date May 17, 2024
Est. primary completion date March 30, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - women were aged > 21 years old - women were not pregnant - women who were undergoing LEEP. Exclusion Criteria: - Women with pelvic infection - Women with abnormal vaginal bleeding - Women with coagulopathy - Women with chronic pain syndromes - Women with psychiatric disorders - Women with the previous hysterectomy with removal of the cervix, - Women with a history of cervical cancer - Women who could not complete follow-up calls

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Chitosan
Chitosan is a biodegradable, natural polyaminosaccharide with a nontoxic, non-allergenic, positively-charged polysaccharide derived from the deacetylation of chitin. Due to its molecular characteristics, chitosan has been used for improved hemostasis. Furthermore, chitosan has an antimicrobial and wound-healing effect

Locations

Country Name City State
Turkey Kemal Güngördük Mentese Mugla
Turkey Mugla Sitki Kocman University Education and Research Hospital Mugla

Sponsors (1)

Lead Sponsor Collaborator
Erzincan Military Hospital

Country where clinical trial is conducted

Turkey, 

Outcome

Type Measure Description Time frame Safety issue
Primary median early postoperative blood loss early postoperative blood loss using the difference in hematocrit values after LEEP and 24 h after the procedure according to the following formula: estimated blood loss = estimated blood volume × (hematocrit 1 - hematocrit 2) / hematocrit 1, where the estimated blood volume in milliliters = body weight in kilograms × 85 6 hours
Secondary Wound healing score The imagine J software program (https://imagej.net/ij/) was used to measure the area of wounds. In order to determine the rate of wound healing, the formula used is [(initial area of treatment wound - remaining wound area)/initial area of treatment wound] × 100%. 1-4 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT00921778 - Long-Term Outcome Following Laparoscopic Supracervical Hysterectomy Performed With and Without Excision of the Endocervix in a Reverse Cone Pattern N/A
Completed NCT02472184 - Optimal Order of Concurrent Office Hysteroscopy and Endometrial Biopsy N/A
Recruiting NCT04612881 - Fitostimoline Vaginal Pessaries in Women With Hysterectomy. Randomized, Perspective, Monoscentric Study.
Completed NCT00339651 - Preliminary Study of Endometrial Hyperplasia Groundwork for a Study to Define Precursors of Endometrial Cancer
Withdrawn NCT04933240 - Tamoxifen Versus Estradiol for Unscheduled Bleeding in Etonogestrel Implant Users, a Randomized Pilot Trial Phase 4
Completed NCT05668806 - RWE Study in the Treatment of Cervical Lesions of Various Etiology
Terminated NCT04277962 - Estimating Blood Loss Using TritonTM in Vaginal Deliveries: A Validation Trial N/A
Active, not recruiting NCT02752282 - Anticipatory Counseling on LNG-IUS Continuation, Utilization and Satisfaction N/A
Completed NCT02385747 - Uterine Cavity Assessment and Endometrial Hormonal Receptors in Women With Peri and Post Menopausal Bleeding N/A
Completed NCT03856307 - Reliability of Simple Sonographic Findings Acquired With Hand-held Apparatuses to Inform Obstetric Diagnosis
Completed NCT01868308 - Screening To Obviate Preterm Birth N/A
Completed NCT05840471 - Tranexamic Acid as an Intervention in Abruptio Placenta N/A
Not yet recruiting NCT05645848 - The Rate and Predictors of Vaginal Bleeding Among Women With Placenta Previa
Completed NCT03074903 - Does Skyla Insertion Timing Impact Bleeding? N/A